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Abstract
One of the most important health concerns in society is the development of nosocomial in-
fections caused by multidrug-resistant pathogens. The purpose of this review is to discuss
the issues in current antibiotic therapies and the ongoing progress of developing new strat-
egies for the treatment of ESKAPE pathogen infections, which is acronymized for Entero-
coccus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species. We not only examine
the current issues caused by multidrug resistance but we also examine the barrier effects
such as bioﬁlm and intracellular localization exploited by these pathogens to avoid antibi-
otic exposure. Recent innovations in nanomedicine approaches and antibody antibiotic
conjugates are reviewed as potential novel approaches for the treatment of bacterial in-
fection, which ultimately may expand the useful life span of current antibiotics.
Introduction
Since the ﬁrst discovery and development of antibi-
otics, successful treatment of bacterial infectious dis-
eases was achieved in a rapid timescale. However,
along with the broad-spread use of antibiotics, the per-
sistence of bacterial infections caused by multidrug-
resistant (MDR) bacteria now poses a signiﬁcant public
health challenges worldwide.
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In 2008, the Infectious Diseases Society of America
proposed the acronym ESKAPE to standardize a group
of deadly bacterial pathogens with rapidly growing
MDR properties, including Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter species (Rice, 2008). These ESKAPE
pathogens were able to “escape” from the biocidal
action of currently marketed antibacterial drugs,
causing increasingly serious life-threatening nosoco-
mial infections, also known as hospital-acquired
infections (HAIs) (Boucher et al., 2009; Slavcovici
et al., 2015).
The English National Point Prevalence Survey (Health
Protection Agency 2012) identiﬁed that 6.4% of
inpatients in 2011 had HAIs in the UK. The Centers for
Disease Control and Prevention estimated that over 2
million infections and about 23,000 deaths per year
worldwide were caused by antibiotic-resistant ESKAPE
pathogens (Najaﬁ et al., 2016). In recent years, the
HAIs problem has caused great concern all over the
world, but with the collaboration of the Infectious
Diseases Society of America, the European Centre for
Disease Prevention and Control (ECDC), and the World
Health Organization (WHO), pharmaceutical industries
were encouraged to reinvestigate their research with
a focus on novel antimicrobial combinations to treat
infections caused by ESKAPE pathogens (Boucher
et al., 2009; European Commission, 2011; WHO, 2015).
However, despite these ongoing efforts and some
notable successes, our therapeutic options for
ESKAPE pathogens, such as vancomycin-resistant
E. faecium, ﬂuoroquinolone-resistant P. aeruginosa,
and carbapenem-resistant Klebsiella species, are
extremely limited. Therefore, further understanding
of resistance mechanisms in these pathogens may lead
to innovative strategies for the development of new
antimicrobial options.
The Issue of Current Therapy
Antibiotic resistance in ESKAPE pathogens
Enterococcus faecium
Enterococcus species are Gram-positive facultative
anaerobes, in which E. faecium is the most clinically
relevant implicated in HAIs (Ciftci et al., 2009; Silva
et al., 2011). These E. faecium infections account for
approximately 40% of all enterococcal infections
currently (Gao et al., 2018). And recently, increasing
resistance of E. faecium to beta-lactam antibiotics has
been reported in health-care facilities (Chen et al.,
2015). Among them, the vancomycin-resistant
E. faecium isolate has emerged in North America during
the late 1980s, with an alarming increase in resistance
of 61% by 2002 (Cetinkaya et al., 2000). In the UK and
Ireland, it was reported by the British Society and
Antimicrobial Chemotherapy that the incidence of
vancomycin-resistant E. faecium had risen from
approximately 20% to over 30% in the period 2001 to
2006 (Brown et al., 2008). Nine different types of
vancomycin resistance genes in Enterococci (Van-A to
E, G, L, M, and N) have been reported, in which Van-A
was the most prevalent worldwide, showing the highest
resistance to all glycopeptides (Cattoir et al., 2013;
Protonotariou et al., 2010).
Staphylococcus aureus
Staphylococcus aureus is a Gram-positive coccal
bacterium, which is present in around 20% of healthy
individuals (Kluytmans et al., 1997; Zeeuwen et al.,
2018). Because of the excessive use of beta-lactam
antibiotics, Staphylococcus species possess a method
of gene transfer to produce beta-lactamase positive
isolates, resulting in 65–85% staphylococcal clinical
isolates being resistant to penicillin G (Santajit et al.,
2016). Methicillin-resistant S. aureus (MRSA) is deﬁned
as a strain of S. aureus that had developed resistance
to beta-lactam antibiotics, including all penicillin,
cephalosporins, and carbapenems. Currently, MRSA
accounts for about 25% of S. aureus isolates, and in
some regions, the prevalence is greater than 50%
(ECDC, 2011). According to the Centers for Disease
Control and Prevention, there are 80,000 cases and
11,000 deaths due to invasive MRSA strains each year
(Najaﬁ et al., 2016). In the clinic, glycopeptide antibi-
otics such as vancomycin were always used as the ﬁrst
choice treatment for MRSA infections. However, since
the ﬁrst reported resistant strains in Japan in the mid-
1990s, these MDR strains have now emerged all over
the world (Chambers et al., 2009).
Klebsiella pneumoniae
As a member of the Enterobacteriaceae family,
K. pneumoniae, a Gram-negative bacterium, frequently
causes lower respiratory tract infection and catheter-
associated urinary tract infection (Navon-Venezia
et al., 2017). Because of the presence of extended-
spectrum beta-lactamases (ESBLs), K. pneumoniae is
not only simply resistant to penicillin and ampicillin but
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also increasingly multidrug resistance to cephalosporin
and ceftazidime (Petrosillo et al., 2013). Historically,
carbapenems were typically used to treat only the most
difﬁcult MDR infections caused by Gram-negative bacte-
ria (Bush, 2010). However, in recent years, carbapenem-
resistant K. pneumonia, harbouring the carbapenemase
gene on resident plasmids, were reported to have
become a signiﬁcant obstacle to treatment by clinicians
in many areas of the world and were associated with high
rates of mortality (Bratu et al., 2005; Naas et al., 2005;
Nordmann et al., 2009; Queenan et al., 2007; Wei
et al., 2007). There are currently three types of
K. pneumoniae producing carbapenemases (KPCs): KPC-
1, KPC-2, and KPC-3 (Yigit et al., 2001; Monteiro et al.,
2009; Humphries et al., 2015). Currently, carbapenem-
resistant K. pneumonia with multidrug resistance only
can be reduced and not completely eradicated;
therefore, effective treatments are urgently needed to
tackle this pathogen.
Acinetobacter baumannii
Acinetobacter baumannii is a non-fermentative Gram-
negative opportunistic pathogen, with the ability to
cause HAIs, particularly respiratory tract, urinary tract,
and wound infections (Abbo et al., 2005; Al Mobarak
et al., 2014; Fournier, 2006), the latter becoming in-
creasingly prevalent in war areas, such as Iraq (Howard
et al., 2012). In the period of January 2002 to August
2004, A. baumannii bloodstream infections were
detected in 85 soldiers in Iraq and Afghanistan; among
them, 35% of the strains were susceptible to only one
type of antibiotic, and worryingly, 4% were resistant
to all antibiotics (Montefour et al., 2008). This has
created pressure on treatment options especially in
those novel isolates with carbapenem resistance. In
addition, imipenem metallo-beta-lactamases and
oxacillinase serine beta-lactamases, both of which are
carbapenemases, have been discovered in A. baumannii
isolates (Queenan et al., 2007; Vila et al., 2007). These
strains show resistance not only to imipenem and colis-
tin but also to traditional antimicrobial compounds,
such as aminoglycosides, ﬂuoroquinolones, and third
generation of cephalosporins (Boucher et al., 2009;
Fournier et al., 2006).
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a Gram-negative rod-
shaped facultative anaerobe, an opportunistic patho-
gen with a mortality rate of 40–60% (Najaﬁ et al.,
2016). P. aeruginosa is found in patients suffering the
genetic condition cystic ﬁbrosis (CF) (Mir et al., 2011).
In CF patients, it has been found that P. aeruginosa
survive in bioﬁlms, thus creating an antibiotic-resistant
shield to treatment in the thick mucus of the CF lung.
Recent reports documented that MDR P. aeruginosa
was not only resistant to carbapenems, aminoglyco-
sides, and quinolones, but also the polymyxins (Hirsch
et al., 2011). A common MDR feature of P. aeruginosa
is the combination of chromosomal AmpC production
and upregulation of an efﬂux pump, which induce
high-level carbapenem resistance (Livermore, 2002).
Additionally, P. aeruginosa can also produce ESBLs and
other resistant enzymes such as KPC, imipenem
metallo-beta-lactamases, and Verona integrin-encoded
metallo-beta-lactamases (BUSH et al., 1995; Liver-
more, 2002). The emergence of carbapenem resistance
and MDR isolates represents a barrier to successful anti-
biotic therapies for the treatment of this microbe.
Enterobacter species
The genus Enterobacter is an important Gram-negative
nosocomial pathogen, causing an increasing number of
serious HAIs, such as bloodstream infection and lower
respiratory infection, resulting in MDR mediated by
plasmid-encoded ESBLs and carbapenemases (Verona
integrin-encoded metallo-beta-lactamases, KPC, and
oxacillinase serine beta-lactamases) (Castanheira
et al., 2011). Other than colistin and tigecycline, these
MDR Enterobacter species have developed resistance to
almost all current available antimicrobials (Deshpande
et al., 2006; Pfaller et al., 2006).
Intracellular pathogens represent reservoirs of
infection
In addition to the various mechanisms to develop resis-
tance towards antimicrobial agents, recent studies
have now shown another mechanism by which ESKAPE
pathogens exhibit antibiotic resistance through the
ability to survive intracellularly in host cells. Persistent
bacterial infections caused by intracellular bacteria
continue to impose signiﬁcant challenges worldwide
(Proctor et al., 2006). In order to maintain their
infection cycle, certain pathogen species are able to
localize inside host cells, creating a niche to reproduce
and spread without damage to the host cells, leading to
severe and latent infections (Imbuluzqueta et al., 2010;
Silva et al., 2013; Hand et al., 2003).
Usually, phagocytes recognize and eliminate bacteria
by phagocytosis. However, some bacteria can survive
through various escape mechanisms. Recent research
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demonstrated that K. pneumoniae is engulfed by
alveolar macrophages and resides inside the cell in a
phagosome, called a Klebsiella-contained vacuole
(Cano et al., 2015). Whilst inside these vacuoles,
K. pneumoniae promotes activation of Akt to arrest
phagosome maturation and avoid fusion into lysosomes,
which would otherwise result in destruction. Another
ESKAPE pathogen, S. aureus, used to be considered as
an extracellular bacterium; however, accumulating
evidence suggests that S. aureus can invade and survive
in either professional or nonprofessional phagocytes,
including keratinocytes, endothelial cells, epithelial
cells, ﬁbroblast, and osteoblasts (Lacoma et al., 2017;
Garzoni et al., 2009; Hanses et al., 2011; Reott et al.,
2008). The adhesion of S. aureus to the host cell surface
results in cytoskeletal rearrangement to allow S. aureus
to move into cells. Once inside a cell, S. aureus can per-
sist and even replicate within the acidic phagolysosome
(Brouillette et al., 2003; Edwards et al., 2011). More-
over, other studies suggested another mechanism that
some other bacteria, including S. aureus, can use to
escape from the phagocytic vacuole to the cytosol
(Fraunholz et al., 2012).
Furthermore, some other pathogens also exhibited
similar mechanisms to maintain their life in host cells.
For example, Coxiella burnetii infects mononuclear
phagocytes, acquiring late endosomal-early lysosomal
markers, and resides inside the acidic vacuoles (Howe
et al., 2010). Mycobacterium tuberculosis was reported
recently that it can create its own vacuole to prevent
phagosome-lysosome fusion (Weiss et al., 2015) and
also has the ability to escape into cytosol by
permeabilizing the phagosome membranes (Jamwal
et al., 2016).
As a consequence, professional phagocytes are not
only unable to eradicate intracellular pathogens but
provide a reservoir of latent infection that represents
a signiﬁcant barrier to successful treatment with
antibiotics.
Treatments for ESKAPE Pathogens
Nano-based drug delivery system
Macrophages are responsible for removing foreign path-
ogens or particles in the blood and tissue via phagocy-
totic pathways (Desjardins et al., 2003; Muppidi
et al., 2011). However, phagocytes harbouring ESKAPE
pathogens, such as S. aureus and K. pneumoniae, act
as “Trojan Horse” to allow these intracellular bacteria
to establish secondary infection foci, resulting in
recurrent systemic infections (Tan et al., 2013).
However, these same phagocytosis pathways could also
be co-utilised to allow antibiotics to be delivered to
macrophages. Theoretically, nano-carriers containing
antibiotics are able to passively accumulate in infection
foci via recognition and uptake by phagocytes. Upon
phagocytosis of particulate drugs, the antibiotic
payload has the potential to be delivered into the
infected cells, therefore enhancing penetration and
release of antibiotics inside the infected cells (Briones
et al., 2008; Bakker-Woudenberg et al., 2004; Pinto-
Alphandary et al., 2000; Schiffelers et al., 2001).
Furthermore, bioﬁlm-associated antimicrobial
resistance associated with ESKAPE pathogens like
P. aeruginosa and K. pneumoniae is also resistant to
antibiotics (Rasamiravaka et al., 2014; Vuotto et al.,
2017). Nano-carriers could act as a protective coat,
shielding against interactions and minimizing inactiva-
tion of drug by bioﬁlm compartments and resident
enzymes. In this scenario, nano-based drug delivery
systems (DDSs) are a promising way to treat either
intracellular and bioﬁlm-forming ESKAPE pathogen
infections. Diverse nano-formulations, such as lipo-
somes and polymeric nanoparticles (NPs), have been
developed and employed for the delivery of antibiotics
to difﬁcult-to-treat bacteria (Table 1).
Liposomes
Liposomes, ﬁrst explored in the 1960s, represent the
most developed DDS platform (Deamer, 2010; Düzgüneş
et al., 2005). They are spherical vesicles composed of
phospholipid bilayers surrounding an aqueous core.
Within the structure, liposomes are capable of carrying
hydrophilic drugs like aminoglycosides in their core or
embed hydrophobic drugs like beta-lactams into the bi-
layers (Drulis-Kawa et al., 2010; Jones, 1995). Various
studies have suggested that liposomal formulation
could signiﬁcantly enhance the antimicrobial effect of
antibiotics against intracellular ESKAPE pathogens. For
example, Pumerantz et al. (2011) demonstrated that
vancomycin-loaded liposomes composed of cholesterol
and 1,2-distearoyl-sn-glycero-3-phosphocholine a
signiﬁcant intracellular reduction in MRSA colony
forming units compared with free drug. Additionally,
liposome formulations have also been shown to exhibit
enhanced therapeutic effects towards bioﬁlm-forming
P. aeruginosa. As reported by Alhajlan et al. (2013),
the bioﬁlm-forming strains of P. aeruginosa were more
susceptible to clarithromycin-encapsulated liposome
than the free drug. However, some drawbacks were
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revealed in the development of antibiotic-loaded lipo-
somes, such as instability of the vesicles and low drug
encapsulation. Therefore, polymeric NPs have been de-
veloped as alternative nano-formulation platforms to
improve stability and drug loading.
Polymeric nanoparticles
Polymeric NPs are prepared from natural or synthetic
polymers with a size between 10 and 1000 nm. They
can be a polymeric matrix with homogenous drug distri-
bution or nano-capsules with drug entrapped in a
Table 1. Nano-based drug delivery systems for ESKAPE pathogens.
Nanoparticles platform
Loaded
antibiotics
Target
pathogen(s) Outcomes Reference
Pyochelin-based
PEGylated liposomes
Cefepime,
imipenem, and
ceftazidime
P. aeruginosa
(MDRPa)
Killed MDRPa within infected
HaCaT keratinocytes without any
cytotoxic effects at four times MIC
concentrations after 72 h
Pushparaj
Selvadoss
et al.
(2017)
DPPC, cholesterol
liposomes
Ciproﬂoxacin P. aeruginosa The ciproﬂoxacin concentration
required to achieve similar bioﬁlm
inhibition was 125-fold lower
compared with free ciproﬂoxacin
Bandara
et al.
(2016)
DA liposomes Chloramphenicol S. aureus
(MRSA)
An inhibition zone about twofold
higher, compared with free drug,
was achieved by DA liposomes. DA
liposomes augmented
antibacterial activity on
keratinocyte-infected MRSA
Hsu et al.
(2017)
Liposome, made by
phosphatidylcholine,
cholesterol, Tween 80,
and stearylamine
Amikacin K. pneumoniae The liposome was able to deliver
entrapped phage inside
macrophages, caused 94.6% killing
of intracellular K. pneumoniae and
showed synergistic activity to
eradicate mature bioﬁlm of
K. pneumoniae
Singla
et al.
(2016)
PLGA nanoparticles Amikacin P. aeruginosa Particles penetrated through the
entire bioﬁlm thickness, more
effective than free drug in bioﬁlm
eradication
Sabaeifard
et al.
(2017)
Mesoporous silica
nanoparticles
Gentamicin S. aureus The inﬂammation-related gene
expression in infected
preosteoblast or macrophage was
downregulated signiﬁcantly after
treatment by the antibiotic loaded
nanoparticles
Yang et al.
(2018)
PpZEV-NPs, made by
PEG-PLGA, Eudragit
E100, and chitosan
derivative
Vancomycin S. aureus
(MRSA)
PpZEV-NPs showed better
antimicrobial activity than free
vancomycin against intracellular
MRSA
Pei et al.
(2017)
CSNPs Cefazolin K. pneumoniae
P. aeruginosa
Excellent antimicrobial potential
of cefazolin-loaded CSNPs was
demonstrated against multidrug-
resistant K. pneumoniae and
P. aeruginosa
Jamil et al.
(2015)
CSNPs, chitosan nanoparticles; DA, deoxycholic acid; DPPC, dipalmitoylphosphatidylcholine; K. pneumoniae, Klebsiella pneumoniae; MDRPa, multidrug-re-
sistant P. aeruginosa; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; PLGA, poly(lactide-co-glycolide); P. aeruginosa, Pseudo-
monas aeruginosa; S. aureus, Staphylococcus aureus.
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polymeric shell (Kreuter, 1991; Soppimath et al., 2001).
Because of the development of advanced nanotechnol-
ogies and new polymers, NPs are currently the subject
of extensive research as passive macrophage targeting
agents, showing an ideal way to target macrophages
to deliver therapeutic effects (Bains et al., 2016;
Spence et al., 2015). Chitosan, a representative of
commonly investigated natural polymers, has been
widely used for mucoadhesive drug delivery and gene
transfection (Kim et al., 2014). Our group previously re-
ported that tobramycin-loaded NPs, made of chitosan,
and then functionalized with dornase alfa, demon-
strated enhanced antibacterial effects on P. aeruginosa,
DNA degradation, and improved NP penetration of CF
sputum (Deacon et al., 2015). O-carboxymethyl chito-
san NPs loaded with tetracycline were reported by
Maya et al. (2012), where the NPs were sixfold more
effective in killing intracellular S. aureus compared
with tetracycline alone in HEK-293 and differentiated
THP-1 macrophage cells proving it to be an efﬁcient
nanomedicine to treat intracellular S. aureus
infections. Another report illustrated that gentamicin-
loaded chitosan/fucoidan NPs were developed to
provide multiple antimicrobial capabilities against
K. pneumoniae, representing an improvement in anti-
microbial efﬁcacy (Huang et al., 2016). Synthetic
polymers have been used for targeted delivery of anti-
biotics to macrophages for the treatment of intracellu-
lar ESKAPE infections. Among them, poly(lactide-co-
glycolide) (PLGA) is a nontoxic, biodegradable, and bio-
compatible copolymer (Rajeev, 2000). Our previous
work demonstrated that gentamicin-loaded PLGA NPs
were able to signiﬁcantly eradicate bioﬁlm-forming
P. aeruginosa, improving the antimicrobial effects of
gentamicin (Abdelghany et al., 2012). Recently, our
group also reported that using an emulsiﬁcation-solvent
evaporation method, PLGA NPs containing gentamicin
could effectively eliminate intracellular K. pneumoniae
in a bacteria and macrophage coculture model (Jiang
et al., 2018). Another study has shown that the
effective delivery of encapsulated antibiotics (genta-
micin and nafcillin) into cells augmented their
therapeutic activity against intraphagosomal S. aureus
(Imbuluzqueta et al., 2011, 2012; Pillai et al., 2008).
Furthermore, nano-formulated DDSs are also used for
other intracellular bacteria, such as M. tuberculosis
(Dollnellan et al., 2017). For example, PLGA NPs
have been previously explored to deliver isoniazid into
M. tuberculosis infected murine bone marrow-derived
macrophages (Faria et al., 2012).
Nano-formulation of antimicrobial treatments
The emergence of MDR ESKAPE pathogens has driven
the urgent need for novel alternatives to antibiotics
and has made researchers consider nano materials
themselves as antibacterial agents. Silver has been
known for its antibacterial activity since the ancient
Egyptians and Greek periods, but it was only recently
discovered that silver ion (Ag+) has broad-spectrum
antimicrobial activity (Klassen, 2000). With the devel-
opment of nanotechnology, it is now possible to use sil-
ver NPs against infections caused by ESKAPE pathogens.
For instance, Bankalgi et al. (2016) demonstrated that
phenolics-coated silver NPs showed strong antibacterial
effects against Gram-negative P. aeruginosa and
Enterobacter aerogenes. Furthermore, Kedziora et al.
(2016) demonstrated that silver nanoform complexed
with amorphous TiO2 exhibits antimicrobial efﬁcacy
against S. aureus and K. pneumoniae. Although silver
NPs show potential in antimicrobial applications, some
adverse events associated with the use of these NPs,
such as reactive oxygen species production, could dam-
age the host cell. As an alternative, gold (AuNPs),
which possess low cytotoxicity, have also been investi-
gated as antimicrobial agents. It was reported that
AuNPs functionalized with ampicillin elicited effective
broad-spectrum bactericidal activity against the
ESKAPE pathogens, P. aeruginosa and E. aerogenes
(Brown et al., 2012). Additionally, Zhao et al. (2013)
reported that pyrimidinethiol-modiﬁed AuNPs
demonstrated synergistic antimicrobial effects against
MDR E. faecium, MDR P. aeruginosa, MRSA, MDR
K. pneumoniae, and MDR A. baumannii. Thus, the
application of AuNPs seems to hold much potential for
the treatment of MDR ESKAPE infectious diseases, but
further developments such as manufacturability and
pharmacokinetics must be addressed.
Some studies demonstrated other NP formulations
that were capable of eliminating ESKAPE pathogens.
For example, Friedman et al. (2011) have described a
nitric oxide-releasing NP with efﬁcacy against not only
MRSA and A. baumannii but also all the clinical isolates
of Streptococcus pyogenes, Enterococcus faecalis,
K. pneumoniae, and P. aeruginosa. Similarly, another
report demonstrated that nitric oxide-releasing silica
NPs could be utilized as novel antibacterial agents
against intracellular P. aeruginosa in L929 mouse ﬁbro-
blasts (Hetrick et al., 2008). Wu et al. (2013) reported
magnetic reduced graphene oxide NPs functionalized
with glutaraldehyde, which provided rapid and
effective killing of up to 99% of S. aureus. Additionally,
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Jones et al. (2008) demonstrated that ZnO NPs have a
wide range of antibacterial effects against a number
of microorganisms, having signiﬁcantly higher antibac-
terial effects on S. aureus than other metal NPs.
Antibody drug conjugation treatments
Antibody drug conjugates developed as “magic bul-
lets” have been successfully developed for cancer
treatment, consisting of monoclonal antibodies specif-
ically targeted to antigen-expressing tumour cells
with cytotoxic drug payloads (Casi et al., 2012; Wang
et al., 2015). This approach has now been exploited
for treatment of infectious diseases – antibody antibi-
otic conjugates (AACs). In AACs, an antibiotic is
conjugated to an antibody to target the bacteria of
interest. Recently, scientists at Genentech have de-
veloped an AAC called THIOMAB™ antibiotic conjugate
aimed at the treatment of intracellular MRSA. This
AAC consists of an antibody that binds the surface of
S. aureus (wall-teichoic acids and pathogen-speciﬁc
polyanionic glycopolymers) and carries the potent
rifalogue antibiotic (Lehar et al., 2015). Once the
bacterium/AAC complex is internalized by host cells,
the host-resident proteases release the antibiotic
payload, so that it can act directly at the site of
intracellular infection (Fig. 1). These researchers
have demonstrated that this AAC could signiﬁcantly
eradicate intracellular S. aureus infections with a
superior therapeutic effect than vancomycin. This
therapeutic (DSTA-46375) is currently in phase I clini-
cal trials. AACs have the potential to modify a broad-
spectrum antibiotic into a pathogen-speciﬁc antibiotic
as a result of the antibody used, therefore minimizing
side effects such as ototoxicity and nephrotoxicity.
However, AACs are complex molecules, so further de-
velopments in design and manufacturing are required
for application against difﬁcult-to-treat ESKAPE
bacterial infections.
Perspective
Given the increasing prevalence of antibiotic resis-
tance, the treatment of ESKAPE pathogens is becoming
increasingly more challenging. Intracellular ESKAPE
pathogens represent a group of bacteria that are
particularly difﬁcult to treat as a result of their intra-
cellular residual location. Pathogen-harbouring phago-
cytes effectively shield the intracellular bacteria from
antibiotics, resulting in difﬁculties in eradicating the
infection as well as limitations in clinical treatment
options. Antibiotic-loaded DDS may represent an
exciting approach for the treatment for intracellular
bacteria in the future using existing and novel antibi-
otics. With the developments of DDS, intracellular
accumulation of these poorly cell-permeable drugs has
Figure 1. A. Model of antibody antibiotic conjugate (AAC). The AAC consists of an anti-S. aureus antibody covalently linked via the intro-
duced cysteines to an antibiotic using a cathepsin-cleavable linker containing a novel quaternary ammonium salt. B. Mechanism of AAC
action. When AAC opsonized bacteria are taken up by host cells, intracellular proteases cleave the linker and readily release the antibiotic
in its active form to kill S. aureus.
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been circumvented, leading to an enhancement of anti-
microbial activities.
A key concept in the strategy of employing nano-
technological delivery systems for ESKAPE intracellular
infections is that the pathogens and the NPs tend to ac-
cumulate in the same cell – the professional phagocytes
of the reticuloendothelial system. It may be possible in
the future to explore more “active” targeting strate-
gies, exempliﬁed by the current interest in AACs.
In conclusion, through reformulation of existing anti-
biotics, it may be possible to extend the useful life span
of these drugs and their ability to treat dangerous intra-
cellular infections.
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